Identification of thienopyridine carboxamides as selective binders of HIV-1 <i>trans</i> Activation Response (TAR) and Rev Response Element (RRE) RNAs
作者:Xue-Dong Li、Li Liu、Liang Cheng
DOI:10.1039/c8ob02753f
日期:——
The synthesis, biochemical and structural studies of two novel thienopyridine carboxamide derivatives that selectively recognize HIV-1 TAR and RRE RNAs were described.
Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
申请人:Siga Technologies, Inc.
公开号:US20130129677A1
公开(公告)日:2013-05-23
Methods and pharmaceutical compositions for treating viral infections, by administering certain thienopyridine derivative compounds in therapeutically effective amounts are disclosed. Methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment of viral infections such as caused by flavivirus is disclosed, i.e., including but not limited to, Dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus.
THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS
申请人:Siga Technologies, Inc.
公开号:US20170121344A1
公开(公告)日:2017-05-04
Methods and pharmaceutical compositions for treating viral infections, by administering certain thienopyridine derivative compounds in therapeutically effective amounts are disclosed. Methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment of viral infections such as caused by flavivirus is disclosed, i.e., including but not limited to, Dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus.
[EN] THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS<br/>[FR] DÉRIVÉS DE THIÉNOPYRIDINE POUR LE TRAITEMENT ET LA PRÉVENTION D'INFECTIONS PAR LE VIRUS DE LA DENGUE
申请人:SIGA TECHNOLOGIES INC
公开号:WO2014089378A1
公开(公告)日:2014-06-12
Methods and pharmaceutical compositions for treating viral infections, by administering certain thienopyridine derivative compounds in therapeutically effective amounts are disclosed. Methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment of viral infections such as caused by flavivirus is disclosed, i.e., including but not limited to, Dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus.
Development of Small Molecules with a Noncanonical Binding Mode to HIV-1 Trans Activation Response (TAR) RNA
作者:Fardokht A. Abulwerdi、Matthew D. Shortridge、Joanna Sztuba-Solinska、Robert Wilson、Stuart F. J. Le Grice、Gabriele Varani、John S. Schneekloth
DOI:10.1021/acs.jmedchem.6b01450
日期:2016.12.22
molecules that bind to RNA potently and specifically are relatively rare. The study of molecules that bind to the HIV-1 transactivation response (TAR) hairpin, a cis-acting HIV genomic element, has long been an important model system for the chemistry of targeting RNA. Here we report the synthesis, biochemical, and structural evaluation of a series of molecules that bind to HIV-1TARRNA. A promising analogue
有效结合RNA的小分子相对较少。长期以来,对与HIV-1反式激活应答(TAR)发夹(一种顺式作用的HIV基因组元件)结合的分子的研究一直是靶向RNA化学的重要模型系统。在这里,我们报告了一系列与HIV-1 TAR RNA结合的分子的合成,生化和结构评估。一个有前途的类似物15保留了最初命中的TAR结合亲和力,并用40μM的IC 50取代了Tat衍生的肽。可溶性类似物2的NMR表征显示此类化合物的非规范结合模式。最后,评估2和15通过引物延伸(SHAPE)分析的选择性2'-羟基酰化反应,表明在体外合成的365-nt HIV-1 5'-非翻译区(UTR)内与TAR结合的特异性。因此,这些化合物表现出与TAR相互作用的新颖且特定的模式,为RNA配体设计提供了重要建议。